AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 860
- Registration Number
- NCT05211895
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT05205161
- Locations
- 🇪🇸
Research Site, Salamanca, Spain
Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients
Completed
- Conditions
- Breast Cancer, HER2
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3136
- Registration Number
- NCT05203458
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: BFF MDI 160/9.6 μgDrug: Open-label Symbicort TBH 320/9 μgDrug: BFF MDI 320/9.6 μg
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 644
- Registration Number
- NCT05202262
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.
Completed
- Conditions
- Heart Failure
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 237
- Registration Number
- NCT05188144
- Locations
- 🇬🇧
Research Site, Coventry, Warwickshire, United Kingdom
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
Completed
- Conditions
- HypokalemiaHeart FailureHyperkalemia
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6950
- Registration Number
- NCT05184998
- Locations
- 🇨🇳
Research Site, Shanghai, Shanghai, China
Zoladex® 10.8 BC RWS
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1176
- Registration Number
- NCT05184257
- Locations
- 🇨🇳
Research Site, Xining, China
A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
Phase 2
Completed
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Drug: 600mg placebo IV
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 272
- Registration Number
- NCT05184062
- Locations
- 🇨🇳
Research Site, Xuzhou, China
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Completed
- Conditions
- Severe Eosinophilic AsthmaNasal Polyps
- Interventions
- Other: FASENRA(benralizumab)
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 273
- Registration Number
- NCT05180357
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Phase 3
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05171816
- Locations
- 🇨🇳
Research Site, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath